The tariff classification of a biopsy site marker in an applicator system from Mexico
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Ruling text
In your letter dated August 7, 2025, you requested a tariff classification ruling. The Mammotome LumiMARK™ Biopsy Site Marker (Internal Part number CA-000622-003) consists of an applicator device (Part number CA-000622) preloaded with a rose-shaped nitinol biopsy site marker (Part number CC-001829-001), packaged in a sterile sealed pouch. The biopsy site marker is a small, self-expanding device made of nitinol, a biocompatible nickel-titanium alloy known for its shape memory and radiopacity.
You state that this allows the marker to be easily visualized in follow-up imaging procedures such as mammography, ultrasound, or MRI, facilitating accurate localization of the biopsy site for future diagnostic or surgical interventions. The nitinol shape-memory property allows the insertion of the marker in a small collapsed form that expands after placement. The expanded shapes are easily identified by X-ray or ultrasound.
The applicator consists of an insertion cannula with markings made of stainless steel, a plunger assembly, and a handle assembly. In clinical use, the Mammotome LumiMARK™ Biopsy Site Marker is used during a breast biopsy procedure. After tissue is extracted from a suspicious area in the breast using a separate biopsy device (not included in this request), the LumiMARK™ is inserted into the same biopsy site. The applicator may be directly inserted into the tissue or guided through a separate biopsy probe.
Ultrasound is usually used to guide the end position of the marker. When in position, the plunger on the applicator device is depressed and the marker is pushed out of the end of the applicator device and is inserted subdermally. Then the applicator device is withdrawn.
The applicable subheading for the Mammotome LumiMARK™ Biopsy Site Marker (Internal Part number CA-000622-003) will be 9018.90.8000, Harmonized Tariff System of United States (HTSUS), which provides for “[i]nstruments and appliances used in medical, surgical, dental or veterinary sciences, including scintigraphic apparatus, other electro-medical apparatus and sight-testing instruments; parts and accessories thereof: [o]ther instruments and appliances and parts and accessories thereof: [o]ther: [o]ther.” The general rate of duty will be free.
Products of Mexico as provided by heading 9903.01.01 in Section XXII, Chapter 99, Subchapter III, U.S. Note 2(a), HTSUS, other than products classifiable under headings 9903.01.02, 9903.01.03, 9903.01.04, and 9903.01.05, HTSUS, will be subject to an additional 25 percent ad valorem rate of duty. At the time of entry, you must report the applicable Chapter 99 heading, i.e. 9903.01.01, in addition to subheadings 9018.90.8000, HTSUS, listed above.
Articles that are entered free of duty under the terms of general note 11 to the HTSUS (U.S.-Mexico-Canada Agreement (USMCA)), including any treatment set forth in subchapter XXIII of Chapter 98 and subchapter XXII of chapter 99 of the HTSUS, will not be subject to the additional ad valorem duties provided for in heading 9903.01.01. If your product is entered duty free as originating under the USMCA, you must report heading 9903.01.04, HTSUS, in addition to subheading 9018.90.8000 HTSUS.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N352128).